Comparative Pharmacology
Head-to-head clinical analysis: TRIACET versus XIPERE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRIACET versus XIPERE.
TRIACET vs XIPERE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Triacetin is a triester of glycerol and acetic acid. Its exact mechanism of action is not fully understood, but it exhibits antifungal activity by disrupting fungal cell membrane integrity and inhibiting fungal growth.
Triamcinolone acetonide is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and stabilizing lysosomal membranes. It also decreases vascular permeability and inhibits cytokine release.
0.5-1 mg orally three times daily; maximum dose 4 mg/day.
The recommended dose is 0.1 mL (containing 0.16 mg triamcinolone acetonide injectable suspension) administered by suprachoroidal injection to the affected eye(s) once every 3 months (every 12 weeks).
None Documented
None Documented
Terminal elimination half-life is approximately 3.5–4 hours in adults with normal renal function; may be prolonged (up to 6–8 hours) in patients with hepatic impairment.
The terminal elimination half-life of triamcinolone acetonide following suprachoroidal administration is approximately 18 hours. This short half-life allows for sustained local effect with minimal systemic accumulation.
Renal, unchanged drug: <1% of dose; metabolites: approximately 20% in urine, remainder in feces via biliary elimination.
XIPERE (triamcinolone acetonide injectable suspension) is primarily eliminated via hepatic metabolism and subsequent renal excretion of metabolites. Approximately 40% of the dose is excreted renally as metabolites, with less than 5% as unchanged drug. Biliary/fecal excretion accounts for about 60% of the dose, mainly as metabolites.
Category C
Category C
Corticosteroid
Corticosteroid